Document is current
Any future updates will be listed below
-
Authors
Falet, Jean-Pierre R. https://orcid.org/0000-0002-7576-2347
Durso-Finley, Joshua
Nichyporuk, Brennan
Schroeter, Julien
Bovis, Francesca
Sormani, Maria-Pia https://orcid.org/0000-0001-6892-104X
Precup, Doina
Arbel, Tal
Arnold, Douglas Lorne https://orcid.org/0000-0003-4266-0106
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (RGPIN-2015-05471)
International Progressive Multiple Sclerosis Alliance
- License Information
-
More Information
Article History
Received: 19 May 2022
Accepted: 9 September 2022
First Online: 26 September 2022
Competing interests
: F.B. has received teaching honoraria from Novartis and has received personal compensation for consulting services from Biogen, Eisai and Chiesi. M.-P.S., has received personal compensation for consulting services and for speaking activities from Merck, Teva, Novartis, Roche, Sanofi Genzyme, Medday, GeNeuro, and Biogen. D.P. works part-time for DeepMind. D.L.A. reports consulting fees from Biogen, Celgene, Frequency Therapeutics, Genentech, Merck, Novartis, Race to Erase MS, Roche, and Sanofi-Aventis, Shionogi, Xfacto Communications, grants from Immunotec and Novartis, and an equity interest in NeuroRx. The remaining authors report no competing interests.
